                                  DC REGULATIONS

DEFINITIONS (§ 17-8399)

8399.1. As used in this Chapter the following terms shall have the meanings
   ascribed:
   
   
   
   Act &#8211; SafeRx Amendment Act of 2008, effective March 26, 2008 (D.C. Law
   17-0131; 55 DCR 4462, published on April 25, 2008 (the Act), and Mayor&#8217;s
   Order 2008-XXX, dated May XX, 2008.
   
   
   
   Applicant- A person applying for a license to practice pharmaceutical
   detailing under this chapter.
   
   
   
   Board &#8211; the Board of Pharmacy, established by § 208 of the Act, D.C.
   Official Code § 3-1202.08.
   
   
   
   Conference &#8211; (1) A meeting, symposium, exposition, exhibit, convention,
   assembly, or like gathering, including meetings of a regional, national, or
   international professional association, society, or body, for the discussion
   of health-related issues consisting of multi-pharmaceutical company or labeler
   representation and targeting a regional, national, or international audience;
   or (2) a scientific or medical educational meeting or symposium that is
   accredited by a nationally recognized healthcare professional education
   accreditation body (e.g., the Accreditation Council for Continuing Medical
   Education, the Accreditation Council for Pharmacy Education, and the American
   Nurses Association).
   
   
   
   Department &#8211; Department of Health
   
   
   
   Director &#8211; Director of the Department
   
   
   
   District of Columbia Family Medical Leave Act &#8211; District of Columbia
   Family Medical Leave Act of 1990, effective October 3, 1990 (D.C. Law 8-181;
   D.C. Official Code § 32-501 et seq.)
   
   
   
   Family Medical Leave Act &#8211; Family Medical Leave Act of 1993, approved
   February 5, 1993 (107 Stat. 7; 29 U.S.C. § 2601 et seq.)
   
   
   
   FDA &#8211; the federal Food and Drug Administration
   
   
   
   HORA &#8211; Health Occupations Revision Act of 1985, effective March 25, 1986
   (D.C. Law 6-99; D.C. Official Code § 3-1201.01 et seq.) Institution of Higher
   Education- as defined in § 101 of the Higher Education Act of 1965, as
   amended, approved October 7, 1998 (112 Stat. 1581; 20 U.S.C. § 1001).
   
   
   
   Labeler &#8211; An entity or person that receives pharmaceutical products from
   a manufacturer or wholesaler and repackages those pharmaceuticals for later
   retail sale and that has a labeler code from the federal Food and Drug
   Administration under 21 C.F.R. § 207.20.
   
   
   
   Manufacturer &#8211; a manufacturer of pharmaceutical products and includes
   subsidiary or affiliate of a manufacturer.
   
   
   
   Medication Advisory Committee &#8211; any committee or panel that is
   responsible for making recommendations or decisions regarding a formulary to
   be used by a health program administered by the government of the District of
   Columbia.
   
   
   
   Multi-pharmaceutical or labeler representation- at least three or more
   pharmaceutical companies or labelers which shall not be subsidiaries, or
   affiliations of the same company or parent company.
   
   
   
   Pharmaceutical Company &#8211; any entity that is engaged in, either directly
   or indirectly, the production, preparation, propagation, compounding,
   manufacturing, conversion or processing of a drug or biologic product,
   including any person acting as its agent or representative.
   
   
   
   Pharmaceutical Detailer:  a person licensed under the Act to engage in the
   practice of pharmaceutical detailing.
   
   
   
   Pharmaceutical Product &#8211; a drug or biologic regulated by the federal
   Food and Drug Administration.
   
   
   
   Practice of Pharmaceutical detailing &#8211; the practice by a representative
   of a pharmaceutical manufacturer or labeler of communicating in person with a
   licensed health professional, or an employee or representative of a licensed
   health
   
   
   
   Sales Call- any in person communication with a health care professional or his
   or her employees or representatives for the direct purpose of selling
   marketing, or promoting a pharmaceutical product, or providing information
   about a pharmaceutical product for the purpose of selling, marketing, or
   promoting such pharmaceutical product on behalf of a pharmaceutical
   manufacturer or labeler.
   
   
   
   
   
   	SOURCE: Final Rulemaking published at 55 DCR 9317 (August 29, 2008); as
   amended by Final Rulemaking published at 56 DCR 2951 (April 17, 2009); as
   amended by Final Rulemaking published at 57 DCR 5739, 5740 (July 2, 2010).
